While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how Penumbra performed in ...

Core Insights - Edwards Lifesciences reported revenue of $1.41 billion for the quarter ended March 2025, reflecting an 11.6% decline year-over-year, with EPS at $0.64 compared to $0.66 in the previous year [1] - The revenue exceeded the Zacks Consensus Estimate of $1.4 billion by 0.71%, while the EPS surpassed the consensus estimate of $0.60 by 6.67% [1] Revenue Performance - Net Sales in Europe were $341.80 million, below the average estimate of $357.01 million, marking a 7.1% decrease year-over-year [4] - Net Sales outside the United States reached $573.80 million, slightly above the estimated $573.77 million, but down 12.7% from the previous year [4] - Net Sales in the United States totaled $838.90 million, below the average estimate of $849.03 million, representing a 10.8% decline year-over-year [4] - Net Sales in Japan were $81.80 million, significantly lower than the estimated $96.40 million, indicating a 26.2% decrease [4] - Net Sales in the Rest of the World amounted to $150.20 million, exceeding the estimate of $120.36 million, but down 16% year-over-year [4] Product Group Performance - Transcatheter Aortic Valve Replacement generated $1.05 billion, surpassing the average estimate of $1.03 billion, with a year-over-year increase of 3.8% [4] - Surgical Structural Heart sales were $250.90 million, slightly below the estimated $254.51 million, reflecting a 5.7% decline year-over-year [4] - Transcatheter Mitral and Tricuspid Therapies achieved $115.20 million, exceeding the average estimate of $113.82 million, with a substantial year-over-year increase of 58% [4] Stock Performance - Shares of Edwards Lifesciences have returned -0.9% over the past month, compared to a -6.6% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Viewpoint - Western New England Bancorp (WNEB) reported a slight increase in revenue but a decrease in earnings per share (EPS) compared to the previous year, indicating mixed financial performance for the quarter ended March 2025 [1]. Financial Performance Summary - Revenue for the quarter was $18.29 million, reflecting a 1.5% increase year-over-year [1]. - EPS was reported at $0.11, down from $0.14 in the same quarter last year [1]. - The revenue fell short of the Zacks Consensus Estimate of $18.53 million, resulting in a surprise of -1.25% [1]. - The EPS also missed the consensus estimate of $0.12, leading to an EPS surprise of -8.33% [1]. Key Metrics Overview - Efficiency ratio was reported at 83%, slightly higher than the estimated 82.2% [4]. - Net Interest Margin stood at 2.5%, matching the average estimate [4]. - Average Interest-Earning Assets were $2.53 billion, exceeding the two-analyst average estimate of $2.51 billion [4]. - Total Non-Interest Income was $2.76 million, below the three-analyst average estimate of $2.93 million [4]. - Net Interest Income was reported at $15.53 million, slightly lower than the average estimate of $15.59 million [4]. Stock Performance - Shares of Western New England Bancorp have returned -8.5% over the past month, compared to a -8.9% change in the Zacks S&P 500 composite [3]. - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3].

Core Insights - Packaging Corp. reported revenue of $2.14 billion for the quarter ended March 2025, reflecting an 8.2% increase year-over-year and matching the Zacks Consensus Estimate, with an EPS of $2.31 compared to $1.72 in the previous year [1] - The company achieved an EPS surprise of +4.52%, with the consensus EPS estimate being $2.21 [1] Financial Performance - Segment Sales for Packaging reached $1.97 billion, aligning with analyst estimates and showing a 9.6% increase from the year-ago quarter [4] - Segment Sales for Corporate and Other were reported at $16.50 million, below the estimated $19.04 million, representing a 5.2% decline year-over-year [4] - Segment Sales for Paper amounted to $154.20 million, falling short of the $161.38 million estimate, indicating a 5.9% decrease compared to the previous year [4] - Segment operating income for Packaging was $284 million, exceeding the estimated $275.21 million [4] - Segment operating loss for Corporate and Other was reported at -$33.40 million, slightly worse than the estimated -$33.32 million [4] - Segment operating income for Paper was $35.60 million, slightly above the estimated $35.20 million [4] Stock Performance - Over the past month, Packaging Corp. shares have returned -9.3%, compared to a -8.9% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]